anti-CD3/anti-guanylate cyclase 2C/anti-CD28 trispecific T-cell engager (Helixon)

N/A

Report date: 2026/03/19 16:53:14

Base Information

Drug Nameanti-CD3/anti-guanylate cyclase 2C/anti-CD28 trispecific T-cell engager (Helixon)
Drug Alias Nametriple CD28 costimulator/anti-CD3/anti-GUCY2C antibody (Helixon)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 agonistsT lymphocytes stimulantsHeat-stable enterotoxin receptor modulators +[5] 
TargetsHeat-stable enterotoxin receptorT cell surface glycoprotein CD3T-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHelixon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHelixon Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A